1. Home
  2. EXEL vs STN Comparison

EXEL vs STN Comparison

Compare EXEL & STN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXEL
  • STN
  • Stock Information
  • Founded
  • EXEL 1994
  • STN 1954
  • Country
  • EXEL United States
  • STN Canada
  • Employees
  • EXEL N/A
  • STN N/A
  • Industry
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • STN Military/Government/Technical
  • Sector
  • EXEL Health Care
  • STN Consumer Discretionary
  • Exchange
  • EXEL Nasdaq
  • STN Nasdaq
  • Market Cap
  • EXEL 12.0B
  • STN 12.0B
  • IPO Year
  • EXEL 2000
  • STN N/A
  • Fundamental
  • Price
  • EXEL $45.40
  • STN $111.74
  • Analyst Decision
  • EXEL Buy
  • STN
  • Analyst Count
  • EXEL 18
  • STN 0
  • Target Price
  • EXEL $44.29
  • STN N/A
  • AVG Volume (30 Days)
  • EXEL 2.7M
  • STN 152.0K
  • Earning Date
  • EXEL 07-28-2025
  • STN 08-13-2025
  • Dividend Yield
  • EXEL N/A
  • STN 0.41%
  • EPS Growth
  • EXEL 237.58
  • STN 14.85
  • EPS
  • EXEL 2.20
  • STN 2.34
  • Revenue
  • EXEL $2,298,922,000.00
  • STN $4,208,787,002.00
  • Revenue This Year
  • EXEL $9.93
  • STN $11.87
  • Revenue Next Year
  • EXEL $13.17
  • STN $7.82
  • P/E Ratio
  • EXEL $20.60
  • STN $47.67
  • Revenue Growth
  • EXEL 24.49
  • STN 16.16
  • 52 Week Low
  • EXEL $22.20
  • STN $73.18
  • 52 Week High
  • EXEL $49.62
  • STN $113.50
  • Technical
  • Relative Strength Index (RSI)
  • EXEL 57.52
  • STN 64.76
  • Support Level
  • EXEL $43.86
  • STN $110.26
  • Resistance Level
  • EXEL $45.52
  • STN $113.50
  • Average True Range (ATR)
  • EXEL 1.44
  • STN 1.46
  • MACD
  • EXEL -0.07
  • STN -0.19
  • Stochastic Oscillator
  • EXEL 39.60
  • STN 65.22

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

About STN Stantec Inc

Stantec Inc is a sustainable engineering, architecture, and environmental consulting company. It offers services through the following business operating units; Environmental Services, Infrastructure, Water, Buildings, and Energy & Resources. Maximum revenue is derived from its Infrastructure business unit, which is engaged in evaluating, planning, and designing infrastructure solutions for transportation, community development, and urban spaces. The company's reportable segments are the United States, which derives maximum revenue, Canada, and Global. These segments provide consulting in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics services in the area of infrastructure and facilities.

Share on Social Networks: